Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 97.08% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-11
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2026-06-30 was 97.08%, a 0.93% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2026-03-31 was 97.43%, a 0.97% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-09-30 was 96.03%, a 4.03% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-06-30 was 96.19%, a 5.89% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month |
|---|---|---|---|
| 2026-06-30 | 97.08% 10-Q · filed 2026-08-11 | 97.43% 10-Q · filed 2026-08-11 | |
| 2026-03-31 | 97.43% 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | 96.03% 10-Q · filed 2025-11-13 | 96.49% 10-Q · filed 2025-11-13 | |
| 2025-06-30 | 96.19% 10-Q · filed 2026-08-11 | 96.49% 10-Q · filed 2026-08-11 | |
| 2025-03-31 | 96.49% 10-Q · filed 2026-05-12 | ||
| 2024-09-30 | 92.31% 10-Q · filed 2025-11-13 | 92.31% 10-Q · filed 2025-11-13 | |
| 2024-06-30 | 90.84% 10-Q · filed 2025-08-11 | 90.84% 10-Q · filed 2025-08-11 | |
| 2024-03-31 | 87.64% 10-Q · filed 2025-05-09 | ||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-18 | 83.70% 10-Q · filed 2024-11-18 | |
| 2023-06-30 | 83.31% 10-Q · filed 2024-08-09 | 83.70% 10-Q · filed 2024-08-09 | |
| 2023-03-31 | 83.70% 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |